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Abstract  
Background: While opioids play a critical role in the management of cancer pain, the ongoing 
opioid epidemic has raised concerns regarding their persistent use and abuse. We lack data-
driven tools in oncology to understand the risk of adverse opioid-related outcomes. This project 
seeks to identify clinical risk factors and create a risk score to help identify patients at risk of 
persistent opioid use and abuse.  
Methods: Within a cohort of 106,732 Veteran cancer survivors diagnosed between 2000 and 
2015, we determined rates of persistent post-treatment opioid use, diagnoses of opioid abuse 
or dependence, and admissions for opioid toxicity. A multivariable logistic regression model 
was used to identify patient, cancer, and treatment risk factors associated with adverse opioid-
related outcomes.  Predictive risk models were developed and validated using a least absolute 
shrinkage and selection operator (LASSO) regression technique.   
Results:  The rate of persistent opioid use in cancer survivors was 8.3% (95% CI=8.1 - 8.4%), the 
rate of opioid abuse or dependence was 2.9% (95%CI=2.8-3.0%), and the rate of opioid-related 
admissions was 2.1% (95%CI=2.0-2.2%).  On multivariable analysis, several patient, 
demographic, cancer and treatment factors were associated with risk of persistent opioid use.  
Predictive models showed a high level of discrimination when identifying individuals at risk of 
adverse opioid-related outcomes including persistent opioid use (area under curve [AUC]= 
0.85), future diagnoses of opioid abuse or dependence (AUC=0.87) and admission for opioid 
abuse or toxicity (AUC=0.78).   
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Conclusion:  This study demonstrates the potential to predict adverse opioid-related outcomes 
among cancer survivors. With further validation, personalized risk stratification approaches 
could guide management when prescribing opioids in cancer patients. 
 
Key Words: Opioid use, opioid abuse, opioid dependency, opioid toxicity, cancer survivorship  
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Pain remains one of the most feared and burdensome symptoms associated with 
cancer, and its curative therapies.1  More than half of cancer patients undergoing curative 
treatment experience pain rated as moderate to severe, warranting opioid use.2,3  Despite the 
accepted role of opioid analgesics in acute pain relief, the utility of opioid use in chronic pain 
(i.e. pain lasting longer three to six months) remains controversial.4,5 Chronic opioid use can 
lead to diminishing analgesic efficacy with the possibility of toxicity including depression, 
sedation, loss of concentration, hyperalgesia and hypogonadism.4,6,7 Additional known risks 
with prolonged opioid use include dependence, misuse, abuse, drug diversion, and 
unintentional overdosing.8 Furthermore, the ongoing opioid epidemic has raised concerns 
among patients and oncology providers regarding addiction and misuse.1 With an estimated 
13.7 million cancer survivors in the United States and two-thirds of newly diagnosed cancer 
patients living more than 5 years, a better understanding of persistent opioid use, abuse and 
toxicity in oncology patients is imperative.6,9  
Optimal pain management with opioids requires a patient-specific assessment of 
benefits and risks.7,8  Along these lines, the American Society of Clinical Oncology (ASCO) 
recommends a risk stratified approach to pain management and prescribing opioids.6  Specific 
risk mitigation strategies include adherence monitoring, drug screening,  alternative pain 
management strategies, judicious opioid use and referral to pain specialists.6  Current 
guidelines for risk stratification, however, are based on expert opinion or instruments validated 
in non-oncology cohorts that may omit risk factors relevant to cancer patients.10–13 An 
evidence-based risk stratification approach could help clinicians better identify those at risk of 
adverse opioid-related events who might benefit from proactive adherence monitoring and 
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mitigation. The purpose of this study was to determine rates and factors associated with 
persistent opioid use, diagnoses of opioid abuse, and admissions for opioid toxicity among a 
large cohort of cancer survivors who received curative intent cancer therapy. Additionally, we 
created and validated predictive models to help provide a clinically applicable approach to 
identifying patients at risk. 
 
Methods 
Data source  
Patients were selected from the Veterans Affairs (VA) Informatics and Computing 
Infrastructure (VINCI) database.14  VINCI is a comprehensive nationwide database that contains 
detailed electronic health record information on all Veterans within the VA healthcare system. 
VINCI contains information on patient demographics, past medical history, medications, 
procedures, diagnoses, emergency room visits, clinic visits, and hospitalizations.14 Among 
cancer patients additional data are collected by trained cancer registrars regarding stage at 
diagnosis, treatment and recurrence in accordance with standardized protocols from the 
American College of Surgeons.15 
 This study cohort included patients diagnosed with one of the twelve most common 
non-cutaneous, non-hematologic malignancies in VA patients (bladder, breast, colon, 
esophagus, stomach, head and neck, kidney, liver, lung, pancreas, prostate, or rectal cancer) 
from 2000 to 2015, treated with definitive local therapy (surgery, radiation therapy (RT) or 
both) and alive without recurrence two years after the initiation of treatment (Supplementary 
Figure 1).  Patients with metastatic disease or unknown stage at diagnosis were excluded.  This 
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study was reviewed and approved by the VA Health Care System. Waivers of consent and 
authorization were granted by the Institutional Revie Board (IRB) and the Research and 
Development Committee of the VA Health Care System (IRB Protocol Number 150169). 
 
Covariates 
Baseline patient, demographic and cancer data were extracted from tumor registry 
data.16 Patient ZIP codes were used to obtain regional high school graduation rates, median 
household income level, and population density (urban or rural).17,18  International 
Classification of Disease (ICD) codes (9th or 10th edition) in the year prior to the start of cancer 
treatment were used to define the NCI-adapted Charlson Comorbidity Index (CCI), which 
excludes cancer-related comorbidities. Similarly, ICD-9 or ICD-10 codes were used to capture 
pre-cancer diagnoses of depression, alcohol abuse, non-opioid drug abuse, or opioid abuse.19–21  
Additionally, we identified ‘high risk’ psychiatric conditions prior to cancer diagnosis which 
included bipolar disorder, schizophrenia, obsessive compulsive disease (OCD) and attention 
deficit disorder (ADD) as defined by Webster and colleagues.10,22  Body mass index at the time 
of cancer diagnosis was classified as healthy weight (18.5-25 kg/m2), underweight (< 18.5 
kg/m2) or overweight (> 25 kg/m2).23   
 
Opioid use 
Opioid use was determined from dispensed medication data in the VA outpatient 
pharmacy database.  Similar to prior studies, patients were defined as opioid naïve if no 
prescriptions were filled from one to twelve months prior to their first day of treatment.24–26  
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Prior chronic opioid use was defined as having filled equal to or more than 120 days’ supply of 
opioids between one to twelve months before treatment, or three opioid prescriptions from 
three to six months prior to treatment.24,25,27 Intermittent opioid use was defined as any opioid 
use from one to twelve months prior to treatment that did not meet criteria for chronic opioid 
use.24  Opioid use in the diagnosis and treatment period included any use extending from one 
month prior to the first day of treatment to 3 months after treatment.24,25    
 
Endpoints 
 The primary endpoint of persistent opioid use was defined with the previously 
published threshold of having filled ≥ 120 days’ supply or ≥10 opioid prescriptions from one to 
two years after the start of curative treatment.28 This interval was selected as a time when 
patients should have completed primary and adjuvant cancer therapy and recovered from 
acute toxicity. Secondary endpoints included diagnoses of opioid abuse or dependence 
identified from ICD-9 and ICD-10 diagnosis codes, and admissions for opioid abuse, dependence 
or toxicity identified from inpatient admissions after the diagnosis date.  Diagnoses of opioid 
abuse and dependence were analyzed together for the purposes of this study and approximate 
mild and moderate/severe opioid use disorder , respectively, as defined by the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-5).29,30 
 
Statistical analysis 
Baseline covariates were compared between patients that became persistent opioid 
users and those that did not using a chi-squared test for categorical variables and a Student’s t-
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test for continuous variables.  We used standard multivariable logistic regression models to 
identify associations between our study endpoints and predictive variables. We chose variables 
for the multivariable models a priori which included patient, demographic, clinical, and 
treatment-related variables. Because toxicities for surgery, radiation and chemotherapy vary by 
cancer type and stage, we suspected a potential interaction between these factors.  
Accordingly, we tested for interaction terms between cancer type and stage and treatment 
factors in our regression models.  Statistical analyses and modeling were performed using R 
version 3.5.1 (https://cran.r-project.org/). All tests were two-sided and a P value of less than 
0.05 was considered statistically significant. 
 
Predictive Modeling 
For the predictive models only, imputation of missing variables for predictive modeling 
was accomplished via multivariate imputation by chained equations (MICE) approach.31   
Covariates were assumed to be missing at random and distribution of missing data was 
evaluated using the MICE R package. In total, imputation replaced missing data for alcohol use 
(14.5% missing), tobacco history (14.4% missing), BMI category (3.5% missing), median income 
(2.3% missing), high school graduation rate (1.9% missing), and rural status (0.3% missing).  A 
sensitivity analysis was also performed by including only complete cases for the logistic 
regression and predictive modeling which generated similar findings (results not shown). The 
cohort was randomly divided 1:1 into a training and test (validation) data set.  Covariates and 
interaction terms described above were selected as potential predictor variables in Least 
Absolute Shrinkage and Selection Operator (LASSO) logistic regression models for each study 
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endpoint.32,33  LASSO regression was selected as a robust supervised-learning approach that 
would facilitate variable selection for this high-dimensional dataset.  We optimized the 
weighted penalty term (ƛ) using 10-fold cross validation, and selecting a final ƛ that was one 
standard error greater than the best-performing ƛ, as per standard practice.34 We also explored 
simpler and more parsimonious models by increasing ƛ until five covariates remained. The 
predictive models were created with the training data set, and discriminative ability of the risk 
score was assessed in the test data set using a Receiver Operator Curve (ROC). An area under 
the curve (AUC) of 0.5 indicates the model was no better than random chance, and an AUC of 
1.0 indicates perfect discrimination.  A predictive risk score was developed using the linear 
predictors from the LASSO logistic regression model. For the persistent opioid use prediction 
model only, we categorized patients into predicted risk groups (low: ≤5% vs. intermediate:  > 5 
and ≤ 25% vs. high >25%) based on cutoffs determined to be clinically relevant a priori. The 
simpler predictive models had similar discriminative ability as the complete models, therefore 
we present the simpler models for each endpoint in the results section and included the more 
complex models in the Supplementary Table 2 and Supplementary Figure 2). 
 
Results 
Rates of Adverse Opioid Events  
Among the 106,732 cancer survivors in this study the overall incidence of persistent 
post-treatment opioid use was 8.3% (95% CI, 8.1 - 8.4%) which varied by cancer type ranging 
from a low of 5.3% (5.1-5.5%) in prostate cancer patients to a high of 19.8% (17.2-22.5%) in 
liver cancer patients (Figure 1). The rates of persistent opioid use after treatment varied 
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substantially by a patient’s history of opioid use prior to their cancer diagnosis. The persistent 
post-treatment opioid use rates were lowest for opioid naïve patients (3.5% [95% CI, 3.3-3.6%]) 
followed by prior intermittent users (15.0% [14.4-15.6%]), and prior chronic users (72.2% [70.9-
73.4%]). Among naïve patients, the rates of opioid use varied by whether patient’s received 
opioids during the diagnostic and treatment period. Those prescribed an opioid during the 
diagnostic and treatment period had rates of persistent post-treatment use of 6.2% (6.0-6.5%), 
compared to 1.5% (1.4-1.6%) of those that did not receive a prescription. The rate of post-
treatment diagnoses of opioid abuse or dependence was 2.9% (2.8-3.0%), and opioid-related 
admissions occurred in 2.1% (2.0-2.2%) of patients. 
 
Factors associated with opioid-related endpoints 
 On multivariable analysis, several factors were associated with the risk of persistent 
opioid use (Figure 2).  Younger age, white race, unemployment at the time of cancer diagnosis, 
lower median income, increased comorbidity, and current or prior tobacco use were all 
associated with increased adjusted odds of persistent opioid use. Prior diagnoses of alcohol 
abuse, non-opioid drug abuse, opioid abuse, and depression were associated with increased 
odds. Prior history of chronic opioid use and prior intermittent use were associated with 
substantially increased odds of persistent opioid use. Among opioid naïve patients those 
without an opioid prescription during the diagnostic or treatment period had a lower risk 
persistent opioid use compared to those who received an opioid prescription. Bladder, breast, 
esophagus, stomach, head and neck, liver, lung and pancreas cancer were associated with 
higher odds compared to prostate cancer. 
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 Stratified analyses evaluating the influence of AJCC stage, local treatment, and 
chemotherapy on the risk of persistent opioid use is presented in Supplementary Table 1. In 
general, stage, local treatment, and chemotherapy use were not associated with persistent 
opioid use outside of a few disease-site specific scenarios. Higher stage colon, lung, and head 
and neck cancer patients had an increased odds of persistent opioid use compared to lower 
stage patients. Definitive radiation therapy was associated with an increased odds of persistent 
opioid use compared to definitive surgery in prostate and lung cancer patients. Kidney cancer 
patients receiving chemotherapy had an increased odds of persistent opioid use compared to 
those who did not receive chemotherapy. 
 Factors associated with the risk of future opioid abuse or dependence and opioid-
related admissions are presented in Figure 2. 
 
Risk score to predict adverse opioid-related endpoints  
Our LASSO regression to create predictive risks scores identified patient, tumor, and 
treatment-related factors associated with the risk of the three opioid-related endpoints. 
Predictive covariates varied across the three different models (see Table 2 for predictive 
factors). Use of chemotherapy was a risk factor associated with an increased adjusted risk of all 
three opioid-related outcomes. Other factors associated with an increased risk varied by model, 
though included history of depression, prior opioid use, prior opioid abuse, alcohol abuse, and 
non-opioid drug abuse. Age was associated with a decreased risk of adverse outcomes. The 
individual models demonstrated a relatively high level of discrimination in predicting persistent 
opioid use (AUC = 0.85), opioid abuse or dependence (0.87), and opioid-related admission 
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(0.78). The predictive models for persistent opioid use effectively stratified patients into low, 
intermediate and high risk groups (Figure 3b). The full predictive model demonstrated 
minimally improved discrimination for persistent opioid use (AUC = 0.87), opioid abuse or 
dependence (0.88), and opioid-related admissions (0.79) (see Supplementary Table 2 for 
predictive factors). We developed an online risk tool for these predictive models 
(www.CancerOpioidRisk.org) to assist with clinical implementation.   
 
Discussion 
Opioids are an effective and often irreplaceable analgesic for acute pain in cancer 
patients.1,6 Opioid use in chronic cancer is, however, complex and providers and patients must 
consider the risks of treatment. Rates of persistent opioid use after curative cancer treatment 
have been estimated to be between 10.4 to 33.3%, although definitions of persistent use vary 
between studies.24,35,36   An additional study showed that cancer survivors had increased rates 
of chronic opioid use when compared to non-cancer controls, though by 6 years after diagnosis 
the rates did not differ.37  Optimally managing cancer patients with opioids requires effective 
risk stratification methods to identify individuals at higher risk of poor outcomes.6  Similar to 
cancer stage informing the management of anti-neoplastic therapy, an accurate prediction of 
future opioid-related morbidity can be used to personalize pain management and mitigate 
adverse outcomes.  Current guidelines suggest strategies including establishing a signed 
treatment agreement, periodic urine drug testing, patient and caregiver education, referrals to 
palliative medicine or a pain specialist, avoidance of high risk formulations and minimizing total 
daily dose for patients at increased risk of adverse opioid-related outcomes.6,38–41  
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This study identified multiple patient, cancer, and treatment factors statistically 
significantly associated with risk for persistent opioid use in cancer patients.  Cancers with more 
intensive, multi-modal therapies had the highest adjusted-risk for persistent opioid use 
including esophagus, pancreas, liver, head-and-neck and lung cancer.  Prior opioid use was 
highly associated with future chronic use.  The rate of persistent use was 72.2% among prior 
chronic users compared to 1.5% of opioid naïve patients that did not receive a prescription 
during treatment. Our results also support prior research demonstrating increased risk for 
opioid use among younger patients, the unemployed, current or former smokers and those 
with a prior diagnosis of depression or drug abuse. 10,26,42–44  Other factors associated with 
opioid risk identified in this study such as race, median income, non-abusive alcohol use, 
comorbidity, BMI and cancer type have not been previously reported.42,45,46 We found no 
association between gender and persistent opioid use, which differs from other studies,10,26,28,43 
though one must consider the skewed gender distribution of our study population within the 
VA healthcare system.  Many patient, cancer and treatment related factors were consistently 
predictive of the three opioid-related study endpoints which likely stems from persistent opioid 
use being a mediator for downstream adverse opioids events. 
The data-driven predictive models developed in this project differ from existing opioid 
risk prediction tools. The Opioid Risk Tool represents a commonly used screening tool 
developed by expert opinion to predict aberrant behavior in non-cancer patients. 10 Select risk 
factors for persistent use in our models agreed with predictors used in the Opioid Risk Tool 
including age, history of drug or alcohol abuse, and depression. In contrast with the Opioid Risk 
Tool, having a high risk psychiatric condition (ADD, OCD or Schizophrenia) in our predictive 
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model was not associated with increased adjusted risk for persistent use among cancer 
survivors, which could be a response to more rigid monitoring or prevention strategies in these 
patients.  Additional screening tools include the Screener and Opioid Assessment for Patients 
with Pain-Revised (SOAPP), its revised edition (SOAPP-R), the Brief Risk Questionnaire (BRQ) 
and the current opioid misuse measure (COMM) – all of which are self-reported questionnaires 
that assess psychologic and behavior patterns identified by experts to be associated with opioid 
misuse.11,47–49 It should be noted that all of these previously developed tools were explicitly 
developed and validated in non-cancer populations. Additionally, one must consider that the 
predictive ability of self-reported questionnaires can be limited by their dependence on 
accurate reporting of potentially incriminating behaviors.48  The domains covered by the 
psychometric questionnaires are largely independent of the factors used in this population-
based study. These inherent differences make direct comparisons between risk prediction 
models difficult, however one could hypothesize that the two approaches may be 
complimentary.   
This study has several limitations worth considering. Most notably, one must consider 
whether the results from a cohort of predominantly male military veterans will generalize to a 
non-military population.  In addition to gender differences, veterans are more likely to have 
health insurance coverage and less likely to live below the poverty line when compared to the 
general population.50  Furthermore, combat veterans have higher rates of exposure to mental 
and physical trauma that could increase their risk for substance abuse or dependence.51  
Validation in a non-VA cohort of cancer patients is required to help understand generalizability 
of our findings and determine the predictive ability for the general population.  
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The retrospective nature of this analysis raises questions surrounding the accuracy of 
ascertaining opioid use, abuse, or dependence from electronic health records. Our observed 
rates of adverse opioid-related events were similar to other studies24,26,36,52,53 , though overall 
these events may be under-reported in cancer patients, especially when using claims-based 
data.52 It is also possible that there was a misclassification of recurrence status and that some 
patients included in this cohort had disease progression and underwent additional salvage 
therapy. The observational population-based nature of this study also precludes the ability to 
evaluate known predictive factors such as prior trauma, family history or focused patient-
directed questions that have been previously shown to be associated with opioid abuse.10,12,13  
The primary endpoint of persistent opioid use is limited to opioid prescriptions prescribed 
within the VA system.  There are also limitations in our definition of opioid abuse or 
dependence, which typically requires the observation a problematic pattern of opioid use 
leading to clinical impairment or distress.29   
Despite these limitations, this current study represents one of the largest 
comprehensive evaluations of persistent opioid use and abuse in cancer survivors, and the first 
to construct a predictive model in oncology patients.24,35,43 The absolute rate of persistent 
opioid use, abuse and dependence was relatively low among this cohort of cancer survivors, 
especially among those without prior opioid use. Improved risk stratification will allow for 
personalized risk assessment and improve the safety of pain management in cancer survivors. 
Future work is needed to externally validate these models, ideally in a prospective setting. 
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TABLES 
 
Table 1. Patient, cancer and treatment characteristics of patients stratified by the primary 
outcome of persistent opioid 1 year after treatment* 
Covariate 
No Persistent Opioid Use 
(n=97,923) 
Persistent Opioid Use 
(n=8,808) 
Age (mean (SD)) 65.02 (8.59) 62.07 (8.05) 
Male (%) 94850 (96.9) 8400 (95.4) 
Race (%)   
   Black 22076 (22.5) 1712 (19.4) 
   Other 2770 (2.8) 221 (2.5) 
   White 73077 (74.6) 6875 (78.1) 
Employed (%) 12145 (12.4) 651 (7.4) 
Married (%) 49416 (50.5) 3971 (45.1) 
Zip Code Metrics   
   Rural (%) 26211 (26.8) 2355 (26.8) 
   % with HS Diploma (mean (SD)) 85.6 (8.3) 85.7 (7.8) 
   Median Income (mean $10k (SD)) 50.1 (1.85) 48.9 (1.69) 
Tobacco Use (%)   
   Current 30143 (30.8) 4054 (46.0) 
   Never 20531 (21.0) 1083 (12.3) 
   Past 32940 (33.6) 2595 (29.5) 
   Unknown 14309 (14.6) 1076 (12.2) 
Alcohol Use (%)   
   Current 37476 (38.3) 3211 (36.5) 
   None 29975 (30.6) 2472 (28.1) 
   Past 16049 (16.4) 2030 (23.0) 
   Unknown 14423 (14.7) 1095 (12.4) 
BMI (%)   
   Healthy Weight 25932 (27.4) 2638 (30.8) 
   Overweight 64845 (68.6) 5302 (61.9) 
   Underweight 3704 (3.9) 623 (7.3) 
Prior Diagnoses   
   Alcohol Abuse (%) 14959 (15.3) 2473 (28.1) 
   Depression (%) 19202 (19.6) 3566 (40.5) 
   High Risk Psychiatric Condition (%) 5078 (5.2) 776 (8.8) 
   Non-Opioid Drug Abuse (%) 6810 (7.0) 1407 (16.0) 
   Opioid Abuse (%) 1384 (1.4) 558 (6.3) 
CCI (%)   
D
ow
nloaded from
 https://academ
ic.oup.com
/jnci/advance-article-abstract/doi/10.1093/jnci/djz200/5618684 by U
niversity of C
alifornia, San D
iego user on 26 N
ovem
ber 2019
  
   0 41292 (42.2) 2857 (32.4) 
   1 18793 (19.2) 1845 (20.9) 
   2 17342 (17.7) 1552 (17.6) 
   3+ 20496 (20.9) 2554 (29.0) 
Prior Opioid Use (%)   
   Opioid Naïve-New Prescription 33383 (34.1) 2216 (25.2) 
   Opioid Naïve-No Prescription 50115 (51.2) 779 (8.8) 
   Prior Chronic Use 1354 (1.4) 3509 (39.8) 
   Prior Intermittent Use 13071 (13.3) 2304 (26.2) 
Primary Cancer (%)   
   Bladder 4946 (5.1) 434 (4.9) 
   Breast 2456 (2.5) 270 (3.1) 
   Colon 10007 (10.2) 630 (7.2) 
   Esophagus 806 (0.8) 164 (1.9) 
   Gastric 586 (0.6) 79 (0.9) 
   Head and Neck 9315 (9.5) 1701 (19.3) 
   Kidney 7142 (7.3) 842 (9.6) 
   Liver 739 (0.8) 182 (2.1) 
   Lung 8132 (8.3) 1409 (16.0) 
   Pancreas 251 (0.3) 44 (0.5) 
   Prostate 51361 (52.5) 2894 (32.9) 
   Rectum 2182 (2.2) 159 (1.8) 
AJCC 7th ed. Stage (%)   
   I 30206 (30.8) 3226 (36.6) 
   II 52384 (53.5) 3531 (40.1) 
   III 11026 (11.3) 1216 (13.8) 
   IV 4307 (4.4) 835 (9.5) 
Local Treatment (%)   
   RT 36160 (36.9) 3118 (35.4) 
   Surgery 57255 (58.5) 5017 (57.0) 
   Surgery + RT 4508 (4.6) 673 (7.6) 
   Chemotherapy (%) 8416 (8.6) 1534 (17.4) 
*The groups significantly differed for all covariates (p < 0.01) except for rural status and rates of 
high school graduation.  P values were calculated with a two-sided Chi-squared test for 
categorical variables and a two-sided t-test for continuous variables.  
Abbreviations: SD, Standard Deviation; HS, High School; BMI, Body Mass Index; CCI, Charlson 
Comorbidity Index; AJCC, American Joint Committee on Cancer; ed., edition; RT, Radiation 
Therapy.   
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Table 2. LASSO logistic regression predictive model covariates by outcome* 
Variable 
Chronic 
opioid use 
Opioid 
abuse 
Opioid 
toxicity 
Intercept -2.670 -2.833 -3.966 
Age (per 10 years) - -0.018 -0.002 
Depression  0.109 - 0.026 
Alcohol Abuse - 0.018 - 
Non-Opioid Drug Abuse - 1.095 0.625 
Past Opioid Drug Abuse - 2.616 2.186 
Prior opioid use    
 Opioid-naïve – New Prescription (REF) - - - 
 Opioid-Naïve – No Prescription -0.726 - -0.045 
 Prior Chronic Use  3.209 - - 
 Prior Intermittent Use 0.554 - - 
 Chemotherapy 0.078 0.877 0.677 
Abbreviations: LASSO, least absolute shrinkage and selection operator; RT, radiation therapy; 
AJCC 7, American Joint Committee on Cancer staging system 7th edition; REF, reference group. 
*Table of log odds covariates from final predictive models, omitting covariates not predictive in 
any model. Cell color gradients with red = increasing probability of an opioid event, and blue 
decreasing probability of an opioid event.  
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Figure Titles and Legends 
 
Figure 1. Rates of adverse opioid events among cancer survivors. Rates of persistent opioid 
use (top), new diagnosis of opioid abuse or dependence (middle) and admission for opioid 
abuse, dependence or toxicity (bottom) by cancer type. Abbreviations: HNC, Head and Neck 
Cancer.  
 
Figure 2. Association of covariates with adverse opioid events.  Forest plot showing 
multivariable adjusted odds ratios of covariates for persistent opioid use (left), a future 
diagnosis of opioid abuse or dependence (middle) or in-patient admission related to opioid 
toxicity (right). Error bars represent 95% confidence intervals.  † Not to scale, OR = 35.42  
(32.71-38.36); ‡ Not to scale, OR = 13.52  (11.99-15.25);  *Not to scale OR = 7.22 (6.29-8.28). 
Abbreviation: ref = reference category.   
 
Figure 3. Validation of parsimonious model.  A) ROC curve showing discrimination of LASSO 
model in predicting persistent opioid use, a future diagnosis of opioid abuse or dependence and 
future admissions for opioid abuse, dependence or toxicity.  B)  Bar plot showing incidence of 
persistent opioid use for the predicted risk groups. 
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Figure 2
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